Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions

B-Cell Acute Lymphoblastic Leukemia, Adult

Interventions

DRUG

CAR-T cells targeting CD19 and CD22

Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion

Trial Locations (1)

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER

NCT04788472 - Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL | Biotech Hunter | Biotech Hunter